19 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
15 May 24
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
4:10pm
for the quarter ended March 31, 2023.
Research and Development (R&D) Expenses. R&D expenses were $21.2 million for the quarter ended March 31, 2024
8-K
EX-99.1
ATHA
Athira Pharma Inc
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
was $100.8 million for the year ended December 31, 2023, compared to $72.5 million for the year ended December 31, 2022.
Research and Development (R&D) Expenses … . R&D expenses were $93.8 million for the year ended December 31, 2023, compared to $61.5 million for the year ended December 31, 2022
8-K
EX-99.1
ATHA
Athira Pharma Inc
9 Nov 23
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
&D) Expenses. R&D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30 … million for the nine months ended September 30, 2023, compared with $56.8 million for the nine months ended September 30, 2022.
Research and Development (R
8-K
EX-99.1
ATHA
Athira Pharma Inc
10 Aug 23
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
, 2023, compared with $35.2 million for the six months ended June 30, 2022.
Research and Development (R&D) Expenses. R&D expenses were $21.6 million … related to increased clinical trial activities, manufacturing activities, headcount and increased preclinical R&D.
General and Administrative (G
8-K
EX-99.1
ATHA
Athira Pharma Inc
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
, compared with $16.6 million for the quarter ended March 31, 2022.
Research and Development (R&D) Expenses. R&D expenses were $21.3 million
8-K
EX-99.1
dm20ec9ftb 3j
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
EX-99.1
z5i57cilumysi
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.1
td0ct
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DEFA14A
6d75fndtn0 queb4
26 Apr 22
Additional proxy soliciting materials
8:17am
DEFA14A
ftho un9ghenav5kag
26 Apr 22
Additional proxy soliciting materials
8:11am
DFAN14A
EX-99.5
2zje99vsfw
22 Apr 22
Additional proxy materials by non-management
10:07am
DEFA14A
br58de vcn2m4090y116
5 Apr 22
Additional proxy soliciting materials
5:03pm
DEFA14A
fhb5n gcxjycdvl8a9
30 Mar 22
Additional proxy soliciting materials
4:00pm
8-K
EX-99.1
fpxni
24 Mar 22
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
4:11pm
8-K
EX-99.1
pww913 ie
10 Nov 21
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
4:11pm
8-K
EX-99.1
rbuqwsiv3zv4o1y
16 Aug 21
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
4:11pm
8-K
EX-99.1
ilh2ed 3cmobtn
13 May 21
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
4:10pm
8-K
EX-99.1
4nrtprcke9
25 Mar 21
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
12:00am
8-K
EX-99.1
eda7ddo8ge1c2k4fhbl
12 Nov 20
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
4:11pm
- Prev
- 1
- Next